The EC approved upadacitinib for active polyarticular JIA in children 2 years and older, based on phase 1 SELECT-YOUTH efficacy and safety data.
|Articles|August 20, 2021
Rheumatoid Arthritis Quiz: 2021 Highlights
Author(s)Lana Pine
Test your knowledge with our Rheumatoid Arthritis: 2021 Highlights quiz!
Advertisement
Is the following statement True or False?
Biologics are generally more effective than conventional first line treatment for early RA in treatment-naïve patients.
Advertisement
Related to this article
August 2026 rheumatology highlights include FDA approval of brepocitinib for dermatomyositis and garetosmab-grts for FOP, and new trial data.
In RA-BRIDGE and RA-BRANCH, baricitinib failed to demonstrate VTE noninferiority in patients with RA enriched for thromboembolic risk factors.
A Phase 2a basket trial produced ACR50 responses in 71% of refractory RA patients at 6 months.
Advertisement
Advertisement